What is Azitra?
Headquartered in Branford, Connecticut, Azitra is redefining the landscape of dermatological therapeutics. By leveraging a sophisticated microbial library of over 1,500 bacterial strains, the company utilizes artificial intelligence and machine learning to develop targeted treatments for rare and chronic skin diseases. Their core focus on engineered proteins and live biotherapeutic products, particularly those involving Staphylococcus epidermidis, positions them at the forefront of the precision medicine sector. Azitra's unique approach to restoring skin function through genetic modification represents a significant shift from traditional topical treatments, offering a highly personalized therapeutic model for patients suffering from conditions such as Netherton syndrome and ichthyosis vulgaris.
How much funding has Azitra raised?
Azitra has raised a total of $33.3M across 4 funding rounds:
Debt
$2.1M
Series A
$14M
Debt
$150K
Series B
$17M
Debt (2018): $2.2M with participation from Bios Partners and Connecticut Innovations
Series A (2019): $14M led by KdT Ventures, Connecticut Innovations, Godfrey Capital, and Bios Partners
Debt (2020): $150K supported by PPP
Series B (2020): $17M featuring Leaps by Bayer, Bios Partners, and Connecticut Innovations
Key Investors in Azitra
Bios Partners
Bios Partners is a venture capital firm focused on identifying and bringing advanced biotech innovations to market in the U.S. They aim to disrupt geographic favoritism in venture capital by investing in compelling scientific opportunities across the Central U.S. that are often overlooked.
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials.
What's next for Azitra?
The infusion of capital from recent funding rounds provides Azitra with the necessary runway to accelerate its clinical trial programs and expand its therapeutic pipeline. As the company transitions from early-stage development to more advanced clinical milestones, the focus will likely shift toward scaling its proprietary platform and strengthening strategic collaborations. By maintaining its commitment to frontier science and data-driven drug discovery, Azitra is well-positioned to address critical unmet medical needs in the dermatology market, potentially setting a new standard for microbiome-based interventions in global healthcare.
See full Azitra company page
